The effects of deregulated DNA damage signalling on cancer chemotherapy response and resistance

Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications

Sørlie, T., Perou, C. M., Tibshirani, R. J., Aas, T., Geisler, S. B., Johnsen, H., Hastie, T. J., Eisen, M. B., van de Rijn, M., Jeffrey, S. S., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.191367098 · Cited by 11,506

Gene expression profiling predicts clinical outcome of breast cancer

van 't Veer, L. J., Dai, H., van de Vijver, M. J., He, Y. D., Hart, A. A. M., Mao, M., Peterse, H. L., van der Kooy, K., Marton, M. J., Witteveen, A. T., et al. (2002) · Nature · doi:10.1038/415530a · Cited by 9,536

Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy

Farmer, H., McCabe, N., Lord, C. J., Tutt, A. N. J., Johnson, D. A., Richardson, T. B., Santarosa, M., Dillon, K. J., Hickson, I., Knights, C., et al. (2005) · Nature · doi:10.1038/nature03445 · Cited by 6,683

Glioma stem cells promote radioresistance by preferential activation of the DNA damage response

Bao, S., Wu, Q., McLendon, R. E., Hao, Y., Shi, Q., Hjelmeland, A. B., Dewhirst, M. W., Bigner, D. D., & Rich, J. N. (2006) · Nature · doi:10.1038/nature05236 · Cited by 6,517

A Strong Candidate for the Breast and Ovarian Cancer Susceptibility Gene BRCA1

Miki, Y., Swensen, J. J., Shattuck-Eidens, D. M., Futreal, P. A., Harshman, K., Tavtigian, S. V., Liu, Q., Cochran, C., Bennett, L. M., Ding, W., et al. (1994) · Science · doi:10.1126/science.7545954 · Cited by 6,069

Multidrug resistance in cancer: role of ATP–dependent transporters

Gottesman, M. M., Fojo, T., & Bates, S. E. (2002) · Nature Reviews Cancer · doi:10.1038/nrc706 · Cited by 5,536

Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase

Bryant, H. E., Schultz, N., Thomas, H. D., Parker, K. M., Flower, D., Lopez, E., Kyle, S., Meuth, M., Curtin, N. J., & Helleday, T. (2005) · Nature · doi:10.1038/nature03443 · Cited by 5,198

The resurgence of platinum-based cancer chemotherapy

Kèlland, L. R. (2007) · Nature reviews. Cancer · doi:10.1038/nrc2167 · Cited by 4,733

In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2

Vassilev, L. T., Vu, B. T., Graves, B., Carvajal, D., Podlaski, F., Filipovic, Z., Kong, N., Kammlott, U., Lukacs, C., Klein, C., et al. (2004) · Science · doi:10.1126/science.1092472 · Cited by 4,661

The DNA Damage Response: Making It Safe to Play with Knives

Ciccia, A., & Elledge, S. J. (2010) · Molecular Cell · doi:10.1016/j.molcel.2010.09.019 · Cited by 4,368

Identification of the breast cancer susceptibility gene BRCA2

Wooster, R., Bignell, G. R., Lancaster, J., Swift, S., Seal, S., Mangion, J., Collins, N., Gregory, S. G., Gumbs, C. E., Micklem, G., et al. (1995) · Nature · doi:10.1038/378789a0 · Cited by 3,645

Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers

Fong, P. C., Boss, D. S., Yap, T. A., Tutt, A., Wu, P., Mergui-Roelvink, M., Mortimer, P., Swaisland, H., Lau, A., O'Connor, M. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0900212 · Cited by 3,634

Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors

Sequist, L. V., Waltman, B. A., Dias-Santagata, D., Digumarthy, S., Turke, A. B., Fidias, P., Bergethon, K., Shaw, A. T., Gettinger, S., Cosper, A. K., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002003 · Cited by 3,499

Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer

Olive, K. P., Jacobetz, M. A., Davidson, C. J., Gopinathan, A., McIntyre, D., Honess, D., Madhu, B., Goldgraben, M. A., Caldwell, M. E., Allard, D., et al. (2009) · Science · doi:10.1126/science.1171362 · Cited by 3,170

The human mutator gene homolog MSH2 and its association with hereditary nonpolyposis colon cancer

Fishel, R. A., Lescoe, M. K., Rao, M. R. S., Copeland, N. G., Jenkins, N. A., Garber, J. E., Kane, M., & Kolodner, R. D. (1993) · Cell · doi:10.1016/0092-8674(93)90546-3 · Cited by 2,884

A decade of exploring the cancer epigenome—biological and translational implications

Baylin, S. B., & Jones, P. A. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3130 · Cited by 2,871

A Chromatin-Mediated Reversible Drug-Tolerant State in Cancer Cell Subpopulations

Sharma, S. V., Lee, D. Y., Li, B., Quinlan, M. P., Takahashi, F., Maheswaran, S., McDermott, U., Azizian, N., Zou, L., Fischbach, M. A., et al. (2010) · Cell · doi:10.1016/j.cell.2010.02.027 · Cited by 2,770

Ubiquitous somatic mutations in simple repeated sequences reveal a new mechanism for colonic carcinogenesis

Ionov, Y., Peinado, M. A., Malkhosyan, S. R., Shibata, D. K., & Perucho, M. (1993) · Nature · doi:10.1038/363558a0 · Cited by 2,691

Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas

Xue, W., Zender, L., Miething, C., Dickins, R. A., Hernando, E., Krizhanovsky, V., Cordon-Cardo, C., & Lowe, S. W. (2007) · Nature · doi:10.1038/nature05529 · Cited by 2,473

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial

Audeh, M. W., Carmichael, J., Penson, R. T., Friedlander, M., Powell, B., Bell-McGuinn, K. M., Scott, C., Weitzel, J. N., Oaknin, A., Loman, N., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60893-8 · Cited by 2,279

Mutations of a mutS homolog in hereditary nonpolyposis colorectal cancer

Leach, F. S., Nicolaides, N. C., Papadopoulos, N., Liu, B., Jen, J., Parsons, R. E., Peltomäki, P., Sistonen, P., Aaltonen, L. A., Nyström, M., et al. (1993) · Cell · doi:10.1016/0092-8674(93)90330-s · Cited by 2,271

Inactivation of the DNA-Repair Gene MGMT and the Clinical Response of Gliomas to Alkylating Agents

Esteller, M., García‐Foncillas, J., Andion, E., Goodman, S. N., Hidalgo, O. F., Vanaclocha, V., Baylin, S. B., & Herman, J. G. (2000) · New England Journal of Medicine · doi:10.1056/nejm200011093431901 · Cited by 2,256

The first 30 years of p53: growing ever more complex.

Levine, A. J., & Oren, M. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2723 · Cited by 1,967

Mutation of a mutL Homolog in Hereditary Colon Cancer

Papadopoulos, N., Nicolaides, N. C., Wei, Y.-F., Ruben, S. M., Carter, K. C., Rosen, C. A., Haseltine, W. A., Fleischmann, R. D., Fraser, C. M., Adams, M. D., et al. (1994) · Science · doi:10.1126/science.8128251 · Cited by 1,822

Restoration of p53 function leads to tumour regression in vivo

Ventura, A., Kirsch, D. G., McLaughlin, M. E., Tuveson, D. A., Grimm, J., Lintault, L., Newman, J., Reczek, E. E., Weissleder, R., & Jacks, T. (2007) · Nature · doi:10.1038/nature05541 · Cited by 1,820

DNA Repair by ERCC1 in Non–Small-Cell Lung Cancer and Cisplatin-Based Adjuvant Chemotherapy

Olaussen, K. A., Dunant, A., Fouret, P. J., Brambilla, E. M., André, F., Haddad, V., Clermont, E., Filipits, M., Pirker, R., Popper, H., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa060570 · Cited by 1,725

Hallmarks of 'BRCAness' in sporadic cancers

Turner, N. C., Tutt, A. N. J., & Ashworth, A. (2004) · Nature reviews. Cancer · doi:10.1038/nrc1457 · Cited by 1,690

53BP1 Inhibits Homologous Recombination in Brca1-Deficient Cells by Blocking Resection of DNA Breaks

Bunting, S. F., Callén, E., Wong, N., Chen, H.-T., Polato, F., Gunn, A., Bothmer, A., Feldhahn, N., Fernandez-Capetillo, O., Cao, L., et al. (2010) · Cell · doi:10.1016/j.cell.2010.03.012 · Cited by 1,671

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial

Tutt, A., Robson, M., Garber, J. E., Domchek, S. M., Audeh, M. W., Weitzel, J. N., Friedlander, M., Arun, B., Loman, N., Schmutzler, R. K., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60892-6 · Cited by 1,655

Genomic Instability and Aging-like Phenotype in the Absence of Mammalian SIRT6

Mostoslavsky, R., Chua, K. F., Lombard, D. B., Pang, W. W., Fischer, M. R., Gellon, L., Liu, P., Mostoslavsky, G., Franco, S., Murphy, M. M., et al. (2006) · Cell · doi:10.1016/j.cell.2005.11.044 · Cited by 1,637

Chk1 is an essential kinase that is regulated by Atr and required for the G 2 /M DNA damage checkpoint

Liu, Q., Guntuku, S., Cui, X.-S., Matsuoka, S., Cortez, D., Tamai, K., Luo, G., Carattini-Rivera, S., DeMayo, F., Bradley, A., et al. (2000) · Genes & Development · doi:10.1101/gad.14.12.1448 · Cited by 1,625

Chk1 and Chk2 kinases in checkpoint control and cancer

Bartek, J., & Lukas, J. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00110-7 · Cited by 1,513

DNA Damage-Induced Activation of p53 by the Checkpoint Kinase Chk2

Hirao, A., Kong, Y., Matsuoka, S., Wakeham, A. C., Ruland, J., Yoshida, H., Liu, D., Elledge, S. J., & Mak, T. W. (2000) · Science · doi:10.1126/science.287.5459.1824 · Cited by 1,311

Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome

Olive, K. P., Tuveson, D. A., Ruhe, Z. C., Yin, B., Willis, N. A., Bronson, R. T., Crowley, D., & Jacks, T. (2004) · Cell · doi:10.1016/j.cell.2004.11.004 · Cited by 1,308

Brca1 Controls Homology-Directed DNA Repair

Moynahan, M. E., Chiu, J. W., Koller, B. H., & Jasin, M. (1999) · Molecular Cell · doi:10.1016/s1097-2765(00)80202-6 · Cited by 1,245

Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers

Sakai, W., Swisher, E. M., Karlan, B. Y., Agarwal, M. K., Higgins, J., Friedman, C., Villegas, E., Jacquemont, C., Farrugia, D. J., Couch, F. J., et al. (2008) · Nature · doi:10.1038/nature06633 · Cited by 1,086

Gain of function of a p53 hot spot mutation in a mouse model of Li-Fraumeni syndrome

Lang, G. A., Iwakuma, T., Suh, Y.-A., Liu, G., Rao, V. A., Parant, J. M., Valentin-Vega, Y. A., Terzian, T., Caldwell, L. C., Strong, L. C., et al. (2004) · Cell · doi:10.1016/j.cell.2004.11.006 · Cited by 1,069

Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound

Bykov, V. J. N., Issaeva, N., Shilov, A., Hultcrantz, M., Pugacheva, E., Chumakov, P., Bergman, J., Wiman, K. G., & Selivanova, G. (2002) · Nature Medicine · doi:10.1038/nm0302-282 · Cited by 1,067

Resistance to therapy caused by intragenic deletion in BRCA2

Edwards, S. L., Brough, R., Lord, C. J., Natrajan, R., Vatcheva, R., Levine, D. A., Boyd, J., Reis-Filho, J. S., & Ashworth, A. (2008) · Nature · doi:10.1038/nature06548 · Cited by 1,011

BRCA2 Is Required for Homology-Directed Repair of Chromosomal Breaks

Moynahan, M. E., Pierce, A. J., & Jasin, M. (2001) · Molecular Cell · doi:10.1016/s1097-2765(01)00174-5 · Cited by 1,007

53BP1 loss rescues BRCA1 deficiency and is associated with triple-negative and BRCA-mutated breast cancers

Bouwman, P., Aly, A., Escandell, J. M., Pieterse, M., Bartkova, J., van der Gulden, H., Hiddingh, S., Thanasoula, M., Kulkarni, A., Yang, Q., et al. (2010) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.1831 · Cited by 1,001

High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs

Rottenberg, S., Jaspers, J. E., Kersbergen, A. J., van der Burg, E., Nygren, A. O. H., Zander, S. A. L., Derksen, P. W. B., de Bruin, M., Zevenhoven, J., Lau, A., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0806092105 · Cited by 975

Review of the Lynch syndrome: history, molecular genetics, screening, differential diagnosis, and medicolegal ramifications

Lynch, H. T., Lynch, P. M., Lanspa, S. J., Snyder, C., Lynch, J. F., & Boland, C. R. (2009) · Clinical Genetics · doi:10.1111/j.1399-0004.2009.01230.x · Cited by 864

Mismatch repair gene defects in sporadic colorectal cancers with microsatellite instability

Liu, B., Nicolaides, N. C., Markowitz, S. D., Willson, J. K. V., Parsons, R. E., Jen, J., Papadopolous, N., Peltomäki, P., de la Chapelle, A., Hamilton, S. R., et al. (1995) · Nature Genetics · doi:10.1038/ng0195-48 · Cited by 801

ABT-888, an Orally Active Poly(ADP-Ribose) Polymerase Inhibitor that Potentiates DNA-Damaging Agents in Preclinical Tumor Models

Donawho, C. K., Luo, Y., Luo, Y., Penning, T. D., Bauch, J. L., Bouska, J. J., Bontcheva-Diaz, V., Cox, B. F., DeWeese, T. L., Dillehay, L. E., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-3039 · Cited by 784

Impaired DNA Damage Response, Genome Instability, and Tumorigenesis in SIRT1 Mutant Mice

Wang, R.-H., Sengupta, K., Li, C., Kim, H., Cao, L., Xiao, C., Kim, S., Xu, X., Yin, Z., Chilton, B. S., et al. (2008) · Cancer Cell · doi:10.1016/j.ccr.2008.09.001 · Cited by 782

Clinical Trial Substantiates the Predictive Value of O-6-Methylguanine-DNA Methyltransferase Promoter Methylation in Glioblastoma Patients Treated with Temozolomide

Hegi, M. E., Diserens, A., Godard, S., Dietrich, P.-Y., Regli, L., Ostermann, S., Otten, P., van Melle, G., de Tribolet, N., & Stupp, R. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0384 · Cited by 782

Small molecule RITA binds to p53, blocks p53–HDM-2 interaction and activates p53 function in tumors

Issaeva, N., Bozko, P. M., Enge, M., Protopopova, M., Verhoef, L. G. G. C., Masucci, M. G., Pramanik, A., & Selivanova, G. (2004) · Nature Medicine · doi:10.1038/nm1146 · Cited by 760

Platinum Resistance: The Role of DNA Repair Pathways

Martin, L. P., Hamilton, T. C., & Schilder, R. J. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-2238 · Cited by 754

DNA damage-induced G2–M checkpoint activation by histone H2AX and 53BP1

Fernández-Capetillo, Ó., Chen, H. T., Celeste, A., Ward, I. M., Romanienko, P. J., Morales, J. C., Naka, K., Xia, Z., Camerini‐Otero, R. D., Motoyama, N., et al. (2002) · Nature Cell Biology · doi:10.1038/ncb884 · Cited by 657

PALB2 is an integral component of the BRCA complex required for homologous recombination repair

Sy, S. M.-H., Huen, M. S. Y., & Chen, J. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0811159106 · Cited by 643

Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors

Mendes‐Pereira, A. M., Martin, S. A., Brough, R., McCarthy, A., Taylor, J. R., Kim, J., Waldman, T. A., Lord, C. J., & Ashworth, A. (2009) · EMBO Molecular Medicine · doi:10.1002/emmm.200900041 · Cited by 642

Human HDAC1 and HDAC2 function in the DNA-damage response to promote DNA nonhomologous end-joining

Miller, K. M., Tjeertes, J. V., Coates, J., Legube, G., Polo, S. E., Britton, S., & Jackson, S. P. (2010) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.1899 · Cited by 629

A stroma-related gene signature predicts resistance to neoadjuvant chemotherapy in breast cancer

Farmer, P. J., Bonnefoi, H. R., Anderle, P., Cameron, D., Wirapati, P., Becette, V., André, S., Piccart, M. J., Campone, M., Brain, E. G. C., et al. (2009) · Nature Medicine · doi:10.1038/nm.1908 · Cited by 618

p53-Deficient Cells Rely on ATM- and ATR-Mediated Checkpoint Signaling through the p38MAPK/MK2 Pathway for Survival after DNA Damage

Reinhardt, H. C., Aslanian, A., Lees, J. A., & Yaffe, M. B. (2007) · Cancer Cell · doi:10.1016/j.ccr.2006.11.024 · Cited by 614

Modeling the Therapeutic Efficacy of p53 Restoration in Tumors

Martins, C. P., Brown-Swigart, L., & Evan, G. I. (2006) · Cell · doi:10.1016/j.cell.2006.12.007 · Cited by 600

Secondary Somatic Mutations RestoringBRCA1/2Predict Chemotherapy Resistance in Hereditary Ovarian Carcinomas

Norquist, B. M., Wurz, K., Pennil, C. C., Garcia, R. L., Gross, J., Sakai, W., Karlan, B. Y., Taniguchi, T., & Swisher, E. M. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.34.2980 · Cited by 593

53BP1, a Mediator of the DNA Damage Checkpoint

Wang, B., Matsuoka, S., Carpenter, P. B., & Elledge, S. J. (2002) · Science · doi:10.1126/science.1076182 · Cited by 578

PALB2 Links BRCA1 and BRCA2 in the DNA-Damage Response

Zhang, F., Ma, J., Wu, J., Ye, L., Cai, H., Xia, B., & Yu, X. (2009) · Current Biology · doi:10.1016/j.cub.2009.02.018 · Cited by 575

Principles of ubiquitin and SUMO modifications in DNA repair

Bergink, S., & Jentsch, S. (2009) · Nature · doi:10.1038/nature07963 · Cited by 554

Ku DNA end-binding protein modulates homologous repair of double-strand breaks in mammalian cellsPreprint

Pierce, A. J., Hu, P., Han, M., Ellis, N. A., & Jasin, M. (2001) · Genes & Development · doi:10.1101/gad.946401 · Cited by 514

Anticancer Chemosensitization and Radiosensitization by the Novel Poly(ADP-ribose) Polymerase-1 Inhibitor AG14361

Calabrese, C. R., Almassy, R., Barton, S., Batey, M. A., Calvert, A. H., Canan-Koch, S., Durkacz, B. W., Hostomsky, Z., Kumpf, R. A., Kyle, S., et al. (2004) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djh005 · Cited by 487

Aberrant cell cycle checkpoint function and early embryonic death in Chk1−/− micePreprint

Takai, H., Tominaga, K., Motoyama, N., Minamishima, Y. A., Nagahama, H., Tsukiyama, T., Ikeda, K., Nakayama, K., Nakanishi, M., & Nakayama, K. (2000) · Genes & Development · doi:10.1101/gad.14.12.1439 · Cited by 478

Somatic loss of BRCA1 and p53 in mice induces mammary tumors with features of human BRCA1 -mutated basal-like breast cancer

Liu, X., Holstege, H. H., van der Gulden, H. M. L., Treur-Mulder, M., Zevenhoven, J., Velds, A., Kerkhoven, R. M., van Vliet, M. H., Wessels, L. F. A., Peterse, J. L., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0702969104 · Cited by 476

Fanconi anemia is associated with a defect in the BRCA2 partner PALB2

Xia, B., Dorsman, J. C., Ameziane, N., de Vries, Y., Rooimans, M. A., Sheng, Q., Pals, G., Errami, A., Gluckman, E., Llera, J., et al. (2007) · Nature Genetics · doi:10.1038/ng1942 · Cited by 465

Secondary BRCA1 Mutations in BRCA1 -Mutated Ovarian Carcinomas with Platinum Resistance

Swisher, E. M., Sakai, W., Karlan, B. Y., Wurz, K., Urban, N. D., & Taniguchi, T. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-0088 · Cited by 459

p53 gain-of-function cancer mutants induce genetic instability by inactivating ATM

Song, H., Hollstein, M., & Xu, Y. (2007) · Nature Cell Biology · doi:10.1038/ncb1571 · Cited by 456

UCN-01: a potent abrogator of G2 checkpoint function in cancer cells with disrupted p53

Wang, Q., Fan, S., Eastman, A., Worland, P. J., Sausville, E. A., & O'Connor, P. M. (1996) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/88.14.956 · Cited by 453

New Insights into Checkpoint Kinase 1 in the DNA Damage Response Signaling Network

Dai, Y., & Grant, S. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1029 · Cited by 448

p53 polymorphism influences response in cancer chemotherapy via modulation of p73-dependent apoptosis

Bergamaschi, D., Gasco, M., Hiller, L., Sullivan, A., Syed, N., Trigiante, G., Yuluğ, I. G., Merlano, M. C., Numico, G., Comino, A., et al. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00079-5 · Cited by 445

Chk2‐deficient mice exhibit radioresistance and defective p53‐mediated transcription

Takai, H., Naka, K., Okada, Y., Watanabe, M., Harada, N., Saito, S., Anderson, C. W., Appella, E., Nakanishi, M., Suzuki, H., et al. (2002) · The EMBO Journal · doi:10.1093/emboj/cdf506 · Cited by 441

Genetic Interactions in Cancer Progression and Treatment

Ashworth, A., Lord, C. J., & Reis-Filho, J. S. (2011) · Cell · doi:10.1016/j.cell.2011.03.020 · Cited by 431

53BP1 functions in an ATM-dependent checkpoint pathway that is constitutively activated in human cancer

DiTullio, R. A., Mochan, T. A., Venere, M., Bártková, J., Sehested, M., Bártek, J., & Halazonetis, T. D. (2002) · Nature Cell Biology · doi:10.1038/ncb892 · Cited by 412

Chemosensitivity linked to p73 function

Irwin, M. S., Kondo, K., Marín, M. C., Cheng, L. S., Hahn, W. C., & Kaelin, W. G. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00078-3 · Cited by 406

BACH1 is critical for homologous recombination and appears to be the Fanconi anemia gene product FANCJ

Litman, R., Peng, M., Jin, Z., Zhang, F., Zhang, J., Powell, S., Andreassen, P. R., & Cantor, S. B. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.08.004 · Cited by 396

The pathological response to DNA damage does not contribute to p53-mediated tumour suppression

Christophorou, M. A., Ringshausen, I., Finch, A. J., Swigart, L. B., & Evan, G. I. (2006) · Nature · doi:10.1038/nature05077 · Cited by 382

Translating p53 into the clinic

Cheok, C. F., Verma, C. S., Baselga, J., & Lane, D. P. (2011) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2010.174 · Cited by 381

Deletion of Histone Deacetylase 3 Reveals Critical Roles in S Phase Progression and DNA Damage Control

Bhaskara, S., Chyla, B., Amann, J. M., Knutson, S. K., Cortez, D., Sun, Z., & Hiebert, S. W. (2008) · Molecular Cell · doi:10.1016/j.molcel.2008.02.030 · Cited by 369

Interplay among BRCA1, SIRT1, and Survivin during BRCA1-Associated Tumorigenesis

Wang, R.-H., Yin, Z., Kim, H., Xu, X., Cao, L., Lahusen, T. J., Lee, M., Xiao, C., Vassilopoulos, A., Chen, W., et al. (2008) · Molecular Cell · doi:10.1016/j.molcel.2008.09.011 · Cited by 368

Mild hyperthermia inhibits homologous recombination, induces BRCA2 degradation, and sensitizes cancer cells to poly (ADP-ribose) polymerase-1 inhibition

Krawczyk, P. M., Eppink, B., Essers, J., Stap, J., Rodermond, H. M., Odijk, H., Zelensky, A. N., Chris van, B. R. E. E., Stalpers, L. J. A., Buist, M. R., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1101053108 · Cited by 363

Recurrent gross mutations of the PTEN tumor suppressor gene in breast cancers with deficient DSB repair

Saal, L. H., Gruvberger-Saal, S. K., Persson, C., Lövgren, K., Jumppanen, M., Staaf, J., Jönsson, G. B., Pires, M. M., Maurer, M., Holm, K., et al. (2007) · Nature Genetics · doi:10.1038/ng.2007.39 · Cited by 357

Hdac3 is essential for the maintenance of chromatin structure and genome stability

Bhaskara, S., Knutson, S. K., Jiang, G., Chandrasekharan, M. B., Wilson, A. J., Zheng, S., Yenamandra, A., Locke, K., Yuan, J.-L., Bonine-Summers, A. R., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.10.022 · Cited by 353

A Marker of Homologous Recombination Predicts Pathologic Complete Response to Neoadjuvant Chemotherapy in Primary Breast Cancer

Graeser, M., McCarthy, A., Lord, C. J., Savage, K., Hills, M., Salter, J., Orr, N., Parton, M., Smith, I. E., Reis-Filho, J. S., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-1027 · Cited by 336

A function for cyclin D1 in DNA repair uncovered by protein interactome analyses in human cancers

Jirawatnotai, S., Hu, Y., Michowski, W., Elias, J. E., Becks, L., Bienvenu, F., Zagozdzon, A., Goswami, T., Wang, Y. E., Clark, A. B., et al. (2011) · Nature · doi:10.1038/nature10155 · Cited by 333

Functional Restoration of BRCA2 Protein by Secondary BRCA2 Mutations in BRCA2 -Mutated Ovarian Carcinoma

Sakai, W., Swisher, E. M., Jacquemont, C. F., Chandramohan, K. V., Couch, F. J., Langdon, S. P., Wurz, K., Higgins, J., Villegas, E., & Taniguchi, T. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-1178 · Cited by 329

Selective Inhibition of BRCA2-Deficient Mammary Tumor Cell Growth by AZD2281 and Cisplatin

Evers, B., Drost, R., Schut, E., de Bruin, M., van der Burg, E., Derksen, P. W. B., Holstege, H. H., Liu, X., van Drunen, E., Beverloo, H. B., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4953 · Cited by 327

A Selective Requirement for 53BP1 in the Biological Response to Genomic Instability Induced by Brca1 Deficiency

Cao, L., Xu, X., Bunting, S. F., Liu, J., Wang, R.-H., Cao, L. L., Wu, J. J., Peng, T.-N., Chen, J., Nussenzweig, A., et al. (2009) · Molecular Cell · doi:10.1016/j.molcel.2009.06.037 · Cited by 324

Cancer Stem Cells Contribute to Cisplatin Resistance in Brca1/p53 –Mediated Mouse Mammary Tumors

Shafee, N., Smith, C. R., Wei, S., Kim, Y. H., Mills, G. B., Hortobágyi, G. N., Stanbridge, E. J., & Lee, E. Y.-H. P. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-5480 · Cited by 308

Selective induction of chemotherapy resistance of mammary tumors in a conditional mouse model for hereditary breast cancer

Rottenberg, S., Nygren, A. O. H., Pajic, M., van Leeuwen, F. W. B., van der Heijden, I., van de Wetering, K., Liu, X., de Visser, K. E., Gilhuijs, K. G. A., van Tellingen, O., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0702955104 · Cited by 306

The combined status of ATM and p53 link tumor development with therapeutic responsePreprint

Jiang, H., Reinhardt, H. C., Bártková, J., Tommiska, J., BLOMQVIST, C. P., Nevanlinna, H. A., Bártek, J., Yaffe, M. B., & Hemann, M. T. (2009) · Genes & Development · doi:10.1101/gad.1815309 · Cited by 306

PALB2 Functionally Connects the Breast Cancer Susceptibility Proteins BRCA1 and BRCA2

Zhang, F., Fan, Q., Ren, K., & Andreassen, P. R. (2009) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-09-0123 · Cited by 303

Topoisomerase levels determine chemotherapy response in vitro and in vivo

Burgess, D. J., Doles, J. D., Zender, L., Xue, W., Ma, B., McCombie, W. R., Hannon, G. J., Lowe, S. W., & Hemann, M. T. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0803513105 · Cited by 302

In Silico Analysis of Kinase Expression Identifies WEE1 as a Gatekeeper against Mitotic Catastrophe in Glioblastoma

Mir, S. E., Hamer, P. C. D. W., Krawczyk, P. M., Balaj, L., Claes, A., Niers, J. M., van Tilborg, A. A. G., Zwinderman, A. H., Geerts, D., Kaspers, G. J. L., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.08.011 · Cited by 299

Preventing Nonhomologous End Joining Suppresses DNA Repair Defects of Fanconi Anemia

Adamo, A., Collis, S. J., Adelman, C. A., Silva, N., Hořejšı́, Z., Ward, J. D., Martínez-Pérez, E., Boulton, S. J., & Volpe, A. L. (2010) · Molecular Cell · doi:10.1016/j.molcel.2010.06.026 · Cited by 297

Compromised CDK1 activity sensitizes BRCA-proficient cancers to PARP inhibition

Johnson, N., Li, Y., Walton, Z. E., Cheng, K. A., Li, D., Rodig, S. J., Moreau, L. A., Unitt, C., Bronson, R. T., Thomas, H. D., et al. (2011) · Nature Medicine · doi:10.1038/nm.2377 · Cited by 293

Excision Repair Cross-Complementation Group 1 Polymorphism Predicts Overall Survival in Advanced Non-Small Cell Lung Cancer Patients Treated With Platinum-Based Chemotherapy

Zhou, W., Gurubhagavatula, S., Liu, G., Park, S., Neuberg, D. S., Wain, J. C., Lynch, T. J., Li, S., & Christiani, D. C. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0247 · Cited by 291

Enhancing Tumor-Specific Uptake of the Anticancer Drug Cisplatin with a Copper Chelator

Ishida, S., McCormick, F. P., Smith‐McCune, K., & Hanahan, D. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.04.011 · Cited by 290

SIRT1 Regulates the Function of the Nijmegen Breakage Syndrome Protein

Yuan, Z., Zhang, X. M., Sengupta, N., Lane, W. S., & Seto, E. (2007) · Molecular Cell · doi:10.1016/j.molcel.2007.05.029 · Cited by 277

Stage-specific sensitivity to p53 restoration during lung cancer progression

Feldser, D. M., Kostova, K. K., Winslow, M. M., Taylor, S. E., Cashman, C., Whittaker, C. A., Rivera, F. J. S., Resnick, R., Bronson, R. T., Hemann, M. T., et al. (2010) · Nature · doi:10.1038/nature09535 · Cited by 276

BRCA1 RING Function Is Essential for Tumor Suppression but Dispensable for Therapy Resistance

Drost, R., Bouwman, P., Rottenberg, S., Boon, U., Schut, E., Klarenbeek, S., Klijn, C. N., van der Heijden, I., van der Gulden, H. M. L., Wientjens, E., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.11.014 · Cited by 266

Molecular classification of breast carcinomas by comparative genomic hybridization: a specific somatic genetic profile for BRCA1 tumors.

Wessels, L. F. A., van Welsem, T., Hart, A. A. M., Veer, L. J. V., Reinders, M. J. T., & Nederlof, P. M. (2002) · PubMed · Cited by 252

Ku70 Corrupts DNA Repair in the Absence of the Fanconi Anemia Pathway

Pace, P., Mosedale, G., Hodskinson, M. R. G., Rosado, I. V., Sivasubramaniam, M., & Patel, K. J. (2010) · Science · doi:10.1126/science.1192277 · Cited by 248

Selective activation of p53-mediated tumour suppression in high-grade tumours

Junttila, M. R., Karnezis, A. N., Garcia, D. A., Madriles, F., Kortlever, R. M., Rostker, F., Swigart, L. B., Pham, D. M., Seo, Y., Evan, G. I., et al. (2010) · Nature · doi:10.1038/nature09526 · Cited by 247

Ku Regulates the Non-Homologous End Joining Pathway Choice of DNA Double-Strand Break Repair in Human Somatic Cells

Fattah, F. J., Lee, E. H., Weisensel, N. A., Wang, Y., Lichter, N., & Hendrickson, E. A. (2010) · PLoS Genetics · doi:10.1371/journal.pgen.1000855 · Cited by 244

BRCA1 tumor suppression depends on BRCT phosphoprotein binding, but not its E3 ligase activity

Shakya, R., Reid, L. J., Reczek, C. R., Cole, F., Egli, D., Lin, C.-S., deRooij, D. G., Hirsch, S., Ravi, K., Hicks, J. B., et al. (2011) · Science · doi:10.1126/science.1209909 · Cited by 244

Loss of ATM/Chk2/p53 Pathway Components Accelerates Tumor Development and Contributes to Radiation Resistance in Gliomas

Squatrito, M., Brennan, C., Helmy, K. Y., Huse, J. T., Petrini, J. H. J., & Holland, E. C. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.10.034 · Cited by 242

Distinct Roles of Chromatin-Associated Proteins MDC1 and 53BP1 in Mammalian Double-Strand Break Repair

Xie, A., Hartlerode, A. J., Stucki, M., Odate, S., Puget, N., Kwok, A., Nagaraju, G., Yan, C. T., Alt, F. W., Chen, J., et al. (2007) · Molecular Cell · doi:10.1016/j.molcel.2007.12.005 · Cited by 242

Somatic Mosaicism in Fanconi Anemia: Molecular Basis and Clinical Significance

Foe, J. R. L. T., Kwee, M. L., Rooimans, M. A., Oostra, A. B., Veerman, A. J. P., van Weel, M., Pauli, R. M., Shahidi, N., Dokal, I. S., Roberts, I. E., et al. (1997) · European Journal of Human Genetics · doi:10.1159/000484749 · Cited by 238

DNA Damage Activates a Spatially Distinct Late Cytoplasmic Cell-Cycle Checkpoint Network Controlled by MK2-Mediated RNA Stabilization

Reinhardt, H. C., Hasskamp, P., Schmedding, I., Morandell, S., van Vugt, M. A. T. M., Wang, X., Linding, R., Ong, S., Weaver, D. T., Carr, S. A., et al. (2010) · Molecular Cell · doi:10.1016/j.molcel.2010.09.018 · Cited by 234

A DNA Damage Response Screen Identifies RHINO, a 9-1-1 and TopBP1 Interacting Protein Required for ATR Signaling

Cotta‐Ramusino, C., McDonald, E. R., Hurov, K. E., Sowa, M. E., Harper, J. W., & Elledge, S. J. (2011) · Science · doi:10.1126/science.1203430 · Cited by 229

Error-prone translesion synthesis mediates acquired chemoresistance

Xie, K., Doles, J. D., Hemann, M. T., & Walker, G. C. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1011412107 · Cited by 228

ERCC1 Codon 118 Polymorphism Is a Predictive Factor for the Tumor Response to Oxaliplatin/5-Fluorouracil Combination Chemotherapy in Patients with Advanced Colorectal Cancer

Viguier, J., Boige, V., Miquel, C., Pocard, M. D., Giraudeau, B., Sabourin, J., Ducreux, M. P., Sarasin, A. R., & Praz, F. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-2216 · Cited by 226

Effect of BRCA mutations on the length of survival in epithelial ovarian tumors.

David, Y. B., Chetrit, A., Hirsh-Yechezkel, G., Friedman, E., Beck, B. D., Beller, U., Ben-Baruch, G., Fishman, A., Levavi, H., Lubin, F., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.20.2.463 · Cited by 224

SIRT1 Regulates UV-Induced DNA Repair through Deacetylating XPA

Fan, W., & Luo, J. (2010) · Molecular Cell · doi:10.1016/j.molcel.2010.07.006 · Cited by 223

Chronic cisplatin treatment promotes enhanced damage repair and tumor progression in a mouse model of lung cancerPreprint

Oliver, T. G., Mercer, K. L., Sayles, L. C., Burke, J. R., Mendus, D., Lovejoy, K. S., Cheng, M.-H., Subramanian, A., Mu, D., Powers, S., et al. (2010) · Genes & Development · doi:10.1101/gad.1897010 · Cited by 213

Inhibition of poly (ADP-ribose) polymerase activates ATM which is required for subsequent homologous recombination repair

Bryant, H. E. (2006) · Nucleic Acids Research · doi:10.1093/nar/gkl108 · Cited by 212

Spontaneous functional correction of homozygous Fanconi anaemia alleles reveals novel mechanistic basis for reverse mosaicism

Waisfisz, Q., Morgan, N. V., Savino, M., de Winter, J. P., van Berkel, C. G. M., Hoatlin, M. E., Ianzano, L., Gibson, R. A., Arwert, F., Savoia, A., et al. (1999) · Nature Genetics · doi:10.1038/11956 · Cited by 208

An aCGH classifier derived from BRCA1-mutated breast cancer and benefit of high-dose platinum-based chemotherapy in HER2-negative breast cancer patients

Vollebergh, M. A., Lips, E. H., Nederlof, P. M., Wessels, L. F. A., Schmidt, M. K., van Beers, E. H., Cornelissen, S., Holtkamp, M., Froklage, F. E., de Vries, E. G. E., et al. (2010) · Annals of Oncology · doi:10.1093/annonc/mdq624 · Cited by 198

Suppression of Rev3, the catalytic subunit of Polζ, sensitizes drug-resistant lung tumors to chemotherapy

Doles, J., Oliver, T. G., Cameron, E. R., Hsu, G., Jacks, T., Walker, G. C., & Hemann, M. T. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1011409107 · Cited by 190

Histone deacetylase 4 interacts with 53BP1 to mediate the DNA damage response

Kao, G. D., McKenna, W. G., Guenther, M. G., Muschel, R. J., Lazar, M. A., & Yen, T. J. (2003) · The Journal of Cell Biology · doi:10.1083/jcb.200209065 · Cited by 178

SIRT1 deacetylates APE1 and regulates cellular base excision repair

Yamamori, T., DeRicco, J. S., Naqvi, A., Hoffman, T. A., Mattagajasingh, I., Kasuno, K., Jung, S.-B., Kim, C., & Irani, K. (2009) · Nucleic Acids Research · doi:10.1093/nar/gkp1039 · Cited by 176

Comprehensive Analysis of Missense Variations in the BRCT Domain of BRCA1 by Structural and Functional Assays

Lee, M. S., Green, R., Marsillac, S. M., Coquelle, N., Williams, R. S., Yeung, T., Foo, D., Hau, D., Hui, B., Monteiro, Á. N. A., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-4563 · Cited by 173

Functional Identification of Tumor-Suppressor Genes through an In Vivo RNA Interference Screen in a Mouse Lymphoma Model

Bric, A., Miething, C., Bialucha, C. U., Scuoppo, C., Zender, L., Krasnitz, A., Xuan, Z., Zuber, J. A., Wigler, M. H., Hicks, J. B., et al. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.08.015 · Cited by 162

Nucleotide Excision Repair- and Polymerase η-Mediated Error-Prone Removal of Mitomycin C Interstrand Cross-Links

Zheng, H., Wang, X., Warren, A. J., Legerski, R. J., Nairn, R. S., Hamilton, J. W., & Li, L. (2002) · Molecular and Cellular Biology · doi:10.1128/mcb.23.2.754-761.2003 · Cited by 149

Regulation of global genome nucleotide excision repair by SIRT1 through xeroderma pigmentosum C

Ming, M., Shea, C. R., Guo, X., Li, X., Soltani, K., Han, W., & He, Y.-Y. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1010377108 · Cited by 148

Mouse embryonic stem cell–based functional assay to evaluate mutations in BRCA2

Kuznetsov, S. G., Liu, P., & Sharan, S. K. (2008) · Nature Medicine · doi:10.1038/nm.1719 · Cited by 141

Cdk1 Participates in BRCA1-Dependent S Phase Checkpoint Control in Response to DNA Damage

Johnson, N., Cai, D. D., Kennedy, R. D., Pathania, S., Arora, M., Li, Y.-C., D’Andrea, A. D., Parvin, J. D., & Shapiro, G. I. (2009) · Molecular Cell · doi:10.1016/j.molcel.2009.06.036 · Cited by 141

In vivo RNAi screening identifies regulators of actin dynamics as key determinants of lymphoma progression

Meacham, C. E., Ho, E. E., Dubrovsky, E., Gertler, F. B., & Hemann, M. T. (2009) · Nature Genetics · doi:10.1038/ng.451 · Cited by 127

Effect of BRCA Mutations on the Length of Survival in Epithelial Ovarian Tumors

David, Y. B., Chetrit, A., Hirsh‐Yechezkel, G., Friedman, E., Beck, B. D., Beller, U., Ben‐Baruch, G., Fishman, A., Levavi, H., Lubin, F., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.20.2.463 · Cited by 126

The potential of exploiting DNA-repair defects for optimizing lung cancer treatment

Postel-Vinay, S. C., Vanhecke, E., Olaussen, K. A., Lord, C. J., Ashworth, A., & Soria, J. (2012) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2012.3 · Cited by 119

6-Thioguanine Selectively Kills BRCA2-Defective Tumors and Overcomes PARP Inhibitor Resistance

Issaeva, N., Thomas, H. D., Djurenovic, T., Jaspers, J. E., Stoimenov, I., Kyle, S., Pedley, N., Gottipati, P., Zur, R., Sleeth, K. M., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-3416 · Cited by 106

Identification of BRCA1-IRIS, a BRCA1 locus product

ElShamy, W. M., & Livingston, D. M. (2004) · Nature Cell Biology · doi:10.1038/ncb1171 · Cited by 97

The ERCC1/XPF endonuclease is required for completion of homologous recombination at DNA replication forks stalled by inter-strand cross-links

Al-Minawi, A. Z., Lee, Y.-F., Hakansson, D., Johansson, F., Lundin, C., Saleh-Gohari, N., Schultz, N. D., Jenssen, D., Bryant, H. E., Meuth, M., et al. (2009) · Nucleic Acids Research · doi:10.1093/nar/gkp705 · Cited by 93

Limiting the Persistence of a Chromosome Break Diminishes Its Mutagenic Potential

Bennardo, N., Gunn, A., Cheng, A., Hasty, P., & Stark, J. M. (2009) · PLoS Genetics · doi:10.1371/journal.pgen.1000683 · Cited by 82

A genetic screen identifies BRCA2 and PALB2 as key regulators of G2 checkpoint maintenance

Menzel, T., Nähse, V., Kousholt, A. N., Klein, D. K., Lund‐Andersen, C., Lees, M. J., Johansen, J. V., Syljuåsen, R. G., & Sørensen, C. S. (2011) · EMBO Reports · doi:10.1038/embor.2011.99 · Cited by 78

A High-Throughput Pharmaceutical Screen Identifies Compounds with Specific Toxicity against BRCA2-Deficient Tumors

Evers, B., Schut, E., van der Burg, E., Braumuller, T. M., Egan, D. A., Holstege, H. H., Edser, P. A. H., Adams, D. J., Wade‐Martins, R., Bouwman, P., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-2434 · Cited by 78

Expression of human BRCA1 variants in mouse ES cells allows functional analysis of BRCA1 mutations

Chang, S., Biswas, K., Martin, B. K., Stauffer, S., & Sharan, S. K. (2009) · Journal of Clinical Investigation · doi:10.1172/jci39836 · Cited by 72

Allele-specific tumor spectrum in Pten knockin mice

Wang, H., Karikomi, M., Naidu, S. K., Rajmohan, R., Caserta, E., Chen, H., Rawahneh, M., Moffitt, J., Stephens, J. A., Fernández, S., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0912524107 · Cited by 66

A cell-free assay for the functional analysis of variants of the mismatch repair protein MLH1

Drost, M., Zonneveld, J. B. M., van Dijk, L., Morreau, H. M., Tops, C. M. J., Vasen, H. F. A., Wijnen, J., & de Wind, N. (2009) · Human Mutation · doi:10.1002/humu.21180 · Cited by 65

Do predictive signatures really predict response to cancer chemotherapy?

Borst, P., & Wessels, L. F. A. (2010) · Cell Cycle · doi:10.4161/cc.9.24.14326 · Cited by 64

Cooperative functions of Chk1 and Chk2 reduce tumour susceptibility in vivo

Niida, H., Murata, K., Shimada, M., Ogawa, K., Ohta, K., Suzuki, K., Fujigaki, H., Khaw, A. K., Banerjee, B., Hande, M. P., et al. (2010) · The EMBO Journal · doi:10.1038/emboj.2010.218 · Cited by 56

Genetic reversion in an acute myelogenous leukemia cell line from a Fanconi anemia patient with biallelic mutations in BRCA2.

Ikeda, H., Matsushita, M., Waisfisz, Q., Kinoshita, A., Oostra, A. B., Nieuwint, A. W. M., de Winter, J. P., Hoatlin, M. E., Kawai, Y., Sasaki, M. S., et al. (2003) · PubMed · Cited by 55

Targeting Base Excision Repair for Chemosensitization

Adhikari, S., Choudhury, S., Mitra, P. S., Dubash, J., Sajankila, S. P., & Roy, R. (2008) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/187152008784220366 · Cited by 49

A rapid and cell-free assay to test the activity of lynch syndrome-associated MSH2 and MSH6 missense variants

Drost, M., Zonneveld, J. B. M., van Hees‐Stuivenberg, S., Rasmussen, L. J., Hofstra, R. M. W., & de Wind, N. (2011) · Human Mutation · doi:10.1002/humu.22000 · Cited by 48

BRCA1-IRIS Overexpression Promotes Cisplatin Resistance in Ovarian Cancer Cells

Chock, K. L., Allison, J. M., Shimizu, Y., & ElShamy, W. M. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-1352 · Cited by 38

Targeted Radiosensitization of Cells Expressing Truncated DNA Polymerase β

Neijenhuis, S., Verwijs-Janssen, M., van den Broek, L. J., Begg, A. C., & Vens, C. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-3901 · Cited by 34

Drug candidates derailed in case of mistaken identity

Ledford, H. K. (2012) · Nature · doi:10.1038/483519a · Cited by 28

High-dose chemotherapy for high-risk primary and metastatic breast cancer: is another look warranted?

Nieto, Y. L., & Shpall, E. J. (2009) · Current Opinion in Oncology · doi:10.1097/cco.0b013e328324f48b · Cited by 28

Melphalan as a treatment for BRCA -related ovarian carcinoma: can you teach an old drug new tricks?: Figure 1

Osher, D. J., Kushner, Y. B., Arseneau, J., & Foulkes, W. D. (2011) · Journal of Clinical Pathology · doi:10.1136/jcp.2010.086405 · Cited by 22

Identification and functional analysis of novel BRCA1 transcripts, including mouse Brca1-Iris and human pseudo-BRCA1

Pettigrew, C. A., French, J. D., Saunus, J. M., Edwards, S. L., Sauer, A. V., Smart, C. E., Lundström, T., Wiesner, C., Spurdle, A. B., Rothnagel, J. A., et al. (2008) · Breast Cancer Research and Treatment · doi:10.1007/s10549-008-0256-2 · Cited by 18

Cancer drug resistance: an evolving paradigm

Holohan, C., Van Schaeybroeck, S., Longley, D. B., & Johnston, P. G. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3599 · Cited by 4,681

Mechanisms of DNA damage, repair, and mutagenesis

Chatterjee, N., & Walker, G. C. (2017) · Environmental and Molecular Mutagenesis · doi:10.1002/em.22087 · Cited by 2,039

DNA Damage Sensing by the ATM and ATR Kinases

Marechal, A., & Zou, L. (2013) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a012716 · Cited by 1,514

Treatment of muscle‐invasive and advanced bladder cancer in 2020

Patel, V. G., Oh, W. K., & Galsky, M. D. (2020) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.21631 · Cited by 1,038

Rad51-mediated replication fork reversal is a global response to genotoxic treatments in human cells

Zellweger, R., Dalcher, D., Mutreja, K., Berti, M., Schmid, J. A., Herrador, R., Vindigni, A., & Lopes, M. (2015) · The Journal of Cell Biology · doi:10.1083/jcb.201406099 · Cited by 691

DNA repair dysregulation from cancer driver to therapeutic target

Curtin, N. J. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3399 · Cited by 1,051

DNA repair and the contribution to chemotherapy resistance

Nesic, K., Parker, P., Swisher, E. M., & Krais, J. J. (2025) · Genome Medicine · doi:10.1186/s13073-025-01488-8 · Cited by 57

Targeting DNA damage response in cancer therapy

Hosoya, N., & Miyagawa, K. (2014) · Cancer Science · doi:10.1111/cas.12366 · Cited by 309

Targeting DNA damage response pathways in cancer

Groelly, F. J., Fawkes, M., Dagg, R. A., Blackford, A. N., & Tarsounas, M. (2022) · Nature reviews. Cancer · doi:10.1038/s41568-022-00535-5 · Cited by 890

Replication Fork Remodeling and Therapy Escape in DNA Damage Response-Deficient Cancers

Liptay, M., Barbosa, J. S., & Rottenberg, S. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00670 · Cited by 30